Company news
Biofrontera Inc. news in 2024
Biofrontera Inc.'s news releases, calls and decks from 2024, newest first.
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
December 22, 2024
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
November 21, 2024
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
November 12, 2024
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
October 31, 2024
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
October 30, 2024
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
October 13, 2024
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
October 6, 2024
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 13, 2024
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
June 23, 2024
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
May 14, 2024
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
May 5, 2024
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
May 2, 2024
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
March 25, 2024
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
March 14, 2024
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
March 7, 2024
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
February 22, 2024
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
February 19, 2024
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules
February 19, 2024
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
February 4, 2024
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
January 10, 2024